Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations for Inherited Retinal Diseases
Nanoscope Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare has granted both Sakigake (fast-track) and Orphan Drug designations to its lead optogenetic therapy MCO-010 for treating severe inherited retinal diseases, marking the first time a retinal gene therapy has received these combined designations in Japan. The regulatory milestones are expected to accelerate development and global commercialization efforts alongside ongoing FDA and EMA designations. 
Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations for Inherited Retinal Diseases